Target intelligence / Profile preview

Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)

Target
FCGR2A
Molecular classification
Receptor, Transmembrane protein, Fc receptor
01

Overview

Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A, also known as CD32A) is a transmembrane glycoprotein expressed on myeloid cells, including macrophages, monocytes, neutrophils, dendritic cells, and platelets. It functions as an activating Fc receptor that binds the Fc portion of immunoglobulin G (IgG) antibodies and immune complexes, initiating critical immune responses such as phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and the release of inflammatory cytokines. Structurally, FCGR2A contains an intracellular immunoreceptor tyrosine-based activation motif (ITAM) that recruits Syk kinase upon ligand binding to trigger downstream signaling cascades. Dysregulation of FCGR2A is heavily implicated in autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis, as well as thrombotic conditions such as heparin-induced thrombocytopenia (HIT). Additionally, a common single nucleotide polymorphism (H131R) in FCGR2A significantly alters its binding affinity for IgG subclasses, serving as a key biomarker that predicts patient response to therapeutic monoclonal antibodies like rituximab and cetuximab. Therapeutic strategies targeting FCGR2A include the development of specific antagonists, such as the humanized effector-deficient antibody VIB9600 (MEDI9600), to block immune complex-mediated inflammation without triggering platelet activation or anaphylaxis.

Other names
CD32CD32ACDw32Fc-gamma RII-aFc-gamma-RIIaFcRII-aFCG2FCGR2FCGR2A1IGFR2Fc fragment of IgG receptor IIa
02

Mechanism of action

Antagonist, Fc-receptor binding, Receptor internalization

03

Biological functions

Immune responsePhagocytosisAntibody-dependent cellular cytotoxicityCell surface receptor signaling pathwayInflammatory responsePlatelet activationDegranulationCytokine production
04

Disease associations

Autoimmune diseaseInflammationInfectionSystemic lupus erythematosusRheumatoid arthritisHeparin-induced thrombocytopeniaSepsisCardiovascular diseaseKawasaki disease
05

Safety considerations

AnaphylaxisThrombocytopeniaThrombosisSystemic hypersensitivity reactionsImpaired clearance of immune complexesIncreased susceptibility to bacterial infections
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

FCGR2A H131R polymorphism (rs1801274)FCGR2A expression levelsFCGR2A-131H/H genotypeFCGR2A-131R/R genotype

Beyond the preview

Go deeper on Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call